PacBio Narrows 2026 Revenue Guidance, Reaffirms 2028 Cash-Flow Breakeven Goal
Image: TokenPost
PacBio expects $175 million to $185 million in year-end cash and lowered its operating expense outlook to $203 million to $207 million.
Read the full story on TokenPostBeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.
